Fintel reports that on July 23, 2024, EF Hutton initiated coverage of GeoVax Labs (NasdaqCM:GOVX) with a Buy recommendation.
Analyst Price Forecast Suggests 2,681.82% Upside
As of July 4, 2024, the average one-year price target for GeoVax Labs is $73.44/share. The forecasts range from a low of $6.06 to a high of $126.00. The average price target represents an increase of 2,681.82% from its latest reported closing price of $2.64 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for GeoVax Labs is 5MM, an increase of ∞%. The projected annual non-GAAP EPS is -0.62.
What is the Fund Sentiment?
There are 16 funds or institutions reporting positions in GeoVax Labs. This is an increase of 14 owner(s) or 700.00% in the last quarter. Average portfolio weight of all funds dedicated to GOVX is 0.00%, an increase of 14,649.72%. Total shares owned by institutions increased in the last three months by 891,774.07% to 241K shares.
What are Other Shareholders Doing?
Armistice Capital holds 178K shares representing 7.04% ownership of the company.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 19K shares representing 0.76% ownership of the company.
Geode Capital Management holds 11K shares representing 0.44% ownership of the company.
FSMAX - Fidelity Extended Market Index Fund holds 8K shares representing 0.32% ownership of the company.
Tower Research Capital LLC holds 4K shares representing 0.18% ownership of the company.
Geovax Labs Background Information
(This description is provided by the company.)
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
